Advanced searches left 3/3

Cytogenetically Normal Acute Myeloid Leukemia - Europe PMC

Summarized by Plex Scholar
Last Updated: 01 July 2022

* If you want to update the article please login/register

Overexpression of Prohibitin 2 Protein is Associated with Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia.

About 40%-55 percent of all AML cases, cystogenetically normal acute myeloid leukemia accounts for 40%-50%. We measured the expression of prohibitin 2 in CN-AML patients using immunohistochemical staining of paraffin-embedded bone marrow sections from 134 CN-AML patients to determine its clinical relevance in CN-AML. PHB2 protein overexpression was specifically associated with poor prognosis in CN-AML patients, which was strongly related to poor prognosis. PHB2 protein expression status may be used as an independent prognostic indicator in CN-AML.

Source link: https://europepmc.org/article/MED/35470276


Long non-coding RNA LOC644135 is a potential prognostic indicator in cytogenetically normal acute myeloid leukemia.

DESeq2. Differentially expressed lncRNAs between TCGA-AML cohort and GTEx cohorts were discovered by DESeq2. Patients with high expression of LOC644135 in both the TCGA-AML cohort and the TARGET-AML cohort had poor overall prognosis. In particular, a high prevalence of LOC644135 in CN-AML patients in the TCGA-AML cohort indicated poor overall survival and event-free survival in CN-AML patients. In addition, CN-AML patients had higher LOC6441353535 in comparison to normal controls. Conclusion The findings showed that LOC644135 was an independent prognostic factor in AML and gave a new insight into AML therapy development.

Source link: https://europepmc.org/article/MED/35713000


The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing.

We analyzed 156 adult patients with primary cytogenically normal AML for ASXL1 mutations and co-mutations using targeted next-generation sequencing with a panel of 34 genes associated with myeloid neoplasms. ASXL1 mut had a shorter overall survival and Relapse-free survival in the context of intermediate risk, as well as low incidence of Relapse-free survival than ASXL1 wt. ASXL1 mut / TET2 mut genetype revealed a higher OS than ASXL1 mut / TET2 wt, with ASXL1 mut / TET2 mut / TET2 mut / TET2 mut / TET2 mut / DNMT3A wt when coexisting DNMT3A or TET2 mutations, with a poorer RFS than ASXL1 wt /TNMT3A mut /DNMT3A /T2 mut /TNMT3A wt /TNMT3A wt /DNMT3A wt /DNMT3A /TNMT3A /TET2 mut /TET2 mut wt /T2 wt /TNMT3A /TET2 wt /T2 /TET2 wt /T2 /TET2 wt/TET2.

Source link: https://europepmc.org/article/MED/35652795


Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia.

Long non-coding RNA expression levels have been shown to correlate with clinical outcomes of patients with acute myeloid leukemia cytogenetically normal acute leukemia. However, the presence and clinical significance of genetic variants in AML's nucleotide sequences of lncRNA are uncertain. We reviewed total RNA sequencing results of 377 younger adults with CN-AML, who were generally classified as medically impaired by disease and health, herein. In the lncRNA BS5-1074L1. 4 and a cytosine-to-thymidine variant, we discovered a cytosine-to-thymidine variant in the lncRNA SNHG15, which are both associated with longer life of CN-AML patients. Despite differences in treatment protocols and RNA sequencing procedures, the SNHG15 cytosine-to-thymidine variant was also associated with improved results in a large database of CN-AML patients. We conclude that recurrent genetic variants of lncRNA that are present in the leukemic blasts of CN-AML patients have prognostic and potential biological significance.

Source link: https://europepmc.org/article/MED/34261293


BAALC gene expression tells a serious patient outcome tale in NPM1-wild type/FLT3-ITD negative cytogenetically normal-acute myeloid leukemia in adults.

The most common group of AML patients with normal cytogenetics is Acute myeloid leukemia with normal cytogenetics, which is associated with a variable patient outcome. Several studies have reported that the expression of BAALC gene mRNA level is one of the predictive indicators that has been found in several studies. BAALC gene expression in 149 adult CN-AML patients was determined by an investigator in this review. BAALC expression is linked to MYC targets and Ras signalling, according to a pathway review. Patients in NPM1-wild type/FLT3-ITD negative adult CN-AML patients have poor patient outcomes. We conclude that high BAALC expression correlates with poor patient outcomes in NPM1-wild type/FLT3-ITD negative adult CN-AML patients.

Source link: https://europepmc.org/article/MED/35429905

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions